ATOPIC DERMATITIS

This early-stage trial tested a new drug called NM26-2198, a bispecific antibody that blocks two inflammatory signals (IL-4R and IL-31) involved in atopic dermatitis (eczema). The study included 126 healthy volunteers and patients with moderate-to-severe eczema, receiving either …

This study looked at whether a drug called tralokinumab could help adults with eczema who had already tried dupilumab and didn't get enough relief. The plan was to treat 20 people for 24 weeks, but the study was stopped early and only 7 people took part. The main goal was to see …

This study tested a probiotic supplement for children aged 6 months to 3 years with mild-to-moderate eczema. The goal was to see if the probiotic could reduce eczema severity and the need for steroid creams. However, the trial was terminated early and only enrolled 4 children, so…

This study tested an oral medication called SAR444656 in 70 adults with moderate to severe atopic dermatitis (eczema) that was not well controlled with topical treatments. Participants received one of three doses of the drug or a placebo for 16 weeks. The goal was to see if the d…

This study tested a new medicine called LY3454738 in adults with moderate-to-severe atopic dermatitis (eczema). The goal was to see if it could improve skin symptoms like redness and itching. The trial included 234 participants and was stopped early. Results may help understand i…

This early-stage trial tested an experimental drug called XmAb27564 in 23 people with mild-to-severe plaque psoriasis or moderate-to-severe atopic dermatitis. Participants received four doses of the drug or a placebo every two weeks. The main goal was to check safety and tolerabi…

This study tested an experimental drug called IMG-007 in 13 adults with moderate-to-severe atopic dermatitis (eczema) who did not get enough relief from topical treatments. The main goal was to check the drug's safety, and researchers also looked at how the body processes it and …

This study tested an experimental daily pill called RPT193 for adults with moderate-to-severe atopic dermatitis (eczema) that didn't improve with topical creams. The goal was to see if it reduces skin redness, swelling, and itchiness over 16 weeks. The trial involved 229 particip…

This study tested a prescription cream called ruxolitinib on adults with mild-to-moderate eczema who had trouble sleeping because of their condition. The goal was to see if the cream could help them sleep longer and better. The study was stopped early, but it involved 47 particip…

This study looked at how the drug tralokinumab affects the skin of people with moderate to severe atopic dermatitis (eczema). Researchers measured drug levels and immune changes in skin samples after 16 weeks of treatment. The goal was to better understand how the drug works, whi…

This was a very early (Phase 1) study to check the safety of an experimental drug called IPG7236, taken as a pill. The study involved 63 healthy adults aged 18 to 55. The goal was to see how the body handles the drug and if it causes side effects, before testing it in people with…

This study filmed consultations between dermatologists and infants under 6 months old with atopic dermatitis (eczema). Researchers analyzed the videos to identify specific behaviors that might indicate discomfort, since standard itch assessment scales don't work for babies this y…

This study aimed to better understand eczema by collecting data, blood, and skin samples from 69 participants across Canada. It also compared two types of light therapy (broadband vs narrowband UVB) to see which works better for treating eczema. The study was terminated early, so…

This early-phase study aimed to test the safety of a new drug called LY3872386 in healthy volunteers and people with atopic dermatitis (eczema). The trial was terminated early, so no meaningful data on safety or how the body processes the drug were collected. Only 18 participants…